BR112014013495A2 - antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv - Google Patents
antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain ivInfo
- Publication number
- BR112014013495A2 BR112014013495A2 BR112014013495A BR112014013495A BR112014013495A2 BR 112014013495 A2 BR112014013495 A2 BR 112014013495A2 BR 112014013495 A BR112014013495 A BR 112014013495A BR 112014013495 A BR112014013495 A BR 112014013495A BR 112014013495 A2 BR112014013495 A2 BR 112014013495A2
- Authority
- BR
- Brazil
- Prior art keywords
- her3
- antibodies
- domain
- ligand
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
abstract the present invention relates to antibodies or fragments thereof that bind to a non-linear epitope within domain 3 of the her3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. the invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of her3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof. tradução do resumo resumo patente de invenção: "anticorpos para o receptor 3 do fator de crescimento epidérmico (her3) direcionados para o domínio iii e domíniuo iv de her3". a presente invenção refere-se a anticorpos ou seus fragmentos que se ligam a um epítopo não linear dentro do domínio 3 do receptor de her3 e inibem a transdução do sinal dependente do ligante e independente do ligante. a invenção também se refere a anticorpos ou seus fragmentos que se ligam aos resíduos de aminoácidos dentro dos domínios 3-4 de her3 e inibem a transdução do sinal dependente do ligante e independente do ligante; e composições e métodos de uso de tais anticorpos ou seus fragmentos.abstract the present invention relates to antibodies or fragments thereof that bind to a nonlinear epitope within domain 3 of the her3 receptor and inhibit both ligand-dependent and ligand-independent signal transduction. the invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3-4 of her3 and inhibit both ligand-dependent and ligand-independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof. "antibodies to epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3". The present invention relates to antibodies or fragments thereof that bind to a nonlinear epitope within the her3 receptor domain 3 and inhibit ligand-dependent and ligand-independent signal transduction. The invention also relates to antibodies or fragments thereof that bind to amino acid residues within her3 domains 3-4 and inhibit ligand-dependent and ligand-independent signal transduction; and compositions and methods of using such antibodies or fragments thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161566912P | 2011-12-05 | 2011-12-05 | |
PCT/IB2012/056956 WO2013084151A2 (en) | 2011-12-05 | 2012-12-04 | Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014013495A8 BR112014013495A8 (en) | 2017-06-13 |
BR112014013495A2 true BR112014013495A2 (en) | 2017-06-13 |
Family
ID=47561692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014013495A BR112014013495A2 (en) | 2011-12-05 | 2012-12-04 | antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP2788381A2 (en) |
JP (1) | JP2015500830A (en) |
KR (1) | KR20140099315A (en) |
CN (1) | CN104093742A (en) |
AR (1) | AR089085A1 (en) |
AU (1) | AU2012349739A1 (en) |
BR (1) | BR112014013495A2 (en) |
CA (1) | CA2857939A1 (en) |
EA (1) | EA201491120A1 (en) |
IL (1) | IL232950A0 (en) |
IN (1) | IN2014CN04374A (en) |
MX (1) | MX2014006731A (en) |
SG (1) | SG11201402784WA (en) |
TW (1) | TW201331225A (en) |
UY (1) | UY34488A (en) |
WO (1) | WO2013084151A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL301147A (en) * | 2014-02-28 | 2023-05-01 | Merus Nv | Antibody that binds erbb-2 and erbb-3 |
ES2816624T3 (en) | 2014-02-28 | 2021-04-05 | Merus Nv | Antibodies that bind EGFR and ERBB3 |
CN107257691B (en) | 2014-07-16 | 2021-09-21 | 达娜-法勃肿瘤研究所公司 | HER3 inhibition in low-grade serous ovarian cancer |
CN104530237B (en) * | 2014-12-31 | 2017-09-05 | 百泰生物药业有限公司 | Anti- Her1 therapeutic antibodies |
EP3912998A3 (en) | 2015-10-23 | 2022-02-23 | Merus N.V. | Binding molecules that inhibit cancer growth |
JP6729926B2 (en) * | 2016-05-12 | 2020-07-29 | 国立大学法人神戸大学 | ErbB3 activation signal transduction inhibitor and method for screening the same |
JP7203426B2 (en) * | 2016-09-15 | 2023-01-13 | ウニヴェルズィテート シュトゥットガルト | Antigen binding protein for HER3 |
KR101923641B1 (en) * | 2016-11-25 | 2018-11-29 | 재단법인 목암생명과학연구소 | Anti-HER3 antibody and composition for preventing or treating cancer comprising the same |
JP2020511993A (en) | 2017-03-31 | 2020-04-23 | メルス ナムローゼ フェンノートシャップ | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells carrying the NRG1 fusion gene |
WO2019031965A1 (en) | 2017-08-09 | 2019-02-14 | Merus N.V. | Antibodies that bind egfr and cmet |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR056857A1 (en) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES |
US8362215B2 (en) * | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
ES2655737T3 (en) * | 2009-11-13 | 2018-02-21 | Daiichi Sankyo Europe Gmbh | Materials and methods to treat or prevent diseases associated with HER-3 |
ES2566602T3 (en) * | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anti-ErbB3 antibodies |
TW201302793A (en) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding proteins |
ES2657862T3 (en) * | 2011-05-13 | 2018-03-07 | Gamamabs Pharma | Antibodies against HER3 |
EP2736928B1 (en) * | 2011-07-28 | 2019-01-09 | i2 Pharmaceuticals, Inc. | Sur-binding proteins against erbb3 |
-
2012
- 2012-12-04 EP EP12816130.4A patent/EP2788381A2/en not_active Withdrawn
- 2012-12-04 JP JP2014545420A patent/JP2015500830A/en active Pending
- 2012-12-04 UY UY0001034488A patent/UY34488A/en not_active Application Discontinuation
- 2012-12-04 KR KR1020147018336A patent/KR20140099315A/en not_active Application Discontinuation
- 2012-12-04 TW TW101145508A patent/TW201331225A/en unknown
- 2012-12-04 CN CN201280068966.8A patent/CN104093742A/en active Pending
- 2012-12-04 BR BR112014013495A patent/BR112014013495A2/en not_active Application Discontinuation
- 2012-12-04 EA EA201491120A patent/EA201491120A1/en unknown
- 2012-12-04 MX MX2014006731A patent/MX2014006731A/en unknown
- 2012-12-04 SG SG11201402784WA patent/SG11201402784WA/en unknown
- 2012-12-04 IN IN4374CHN2014 patent/IN2014CN04374A/en unknown
- 2012-12-04 AU AU2012349739A patent/AU2012349739A1/en not_active Abandoned
- 2012-12-04 CA CA2857939A patent/CA2857939A1/en not_active Abandoned
- 2012-12-04 WO PCT/IB2012/056956 patent/WO2013084151A2/en active Application Filing
- 2012-12-05 AR ARP120104559A patent/AR089085A1/en unknown
-
2014
- 2014-06-02 IL IL232950A patent/IL232950A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112014013495A8 (en) | 2017-06-13 |
IL232950A0 (en) | 2014-07-31 |
MX2014006731A (en) | 2015-06-04 |
AU2012349739A1 (en) | 2014-06-26 |
CN104093742A (en) | 2014-10-08 |
UY34488A (en) | 2013-07-31 |
SG11201402784WA (en) | 2014-06-27 |
AR089085A1 (en) | 2014-07-30 |
EA201491120A1 (en) | 2015-07-30 |
EP2788381A2 (en) | 2014-10-15 |
JP2015500830A (en) | 2015-01-08 |
WO2013084151A3 (en) | 2014-01-03 |
CA2857939A1 (en) | 2013-06-13 |
IN2014CN04374A (en) | 2015-09-04 |
TW201331225A (en) | 2013-08-01 |
WO2013084151A2 (en) | 2013-06-13 |
KR20140099315A (en) | 2014-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014013495A8 (en) | antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv | |
BR112014013568A2 (en) | epidermal growth factor 3 (her3) receptor antibodies directed to her3 domain ii | |
CY1123145T1 (en) | ANTI-CD40 ANTIBODIES | |
CL2012003093A1 (en) | Multivalent isolated antibody that has at least two receptor binding domains for two different binding sites of a lrp6 target receptor that inhibit a canonical wnt signal transduction pathway; biparatopic isolated antibody that binds lrp6; nucleic acid encoding it; vector comprising said nucleic acid; pharmaceutical composition comprising a multivalent anti-lrp6 antibody; method of obtaining said antibody; and its use to treat cancer. | |
JO3118B1 (en) | Compositions and methods for antibodies targeting complement protein c5 | |
BR112014006390A2 (en) | antibodies, variable domains and chains made especially for human use | |
GEP201706605B (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
WO2011119979A3 (en) | Antibodies to muc16 and methods of use thereof | |
MX353706B (en) | Antibodies binding preferentially human csf1r extracellular domain 4 and their use. | |
BR112014015111A2 (en) | p-factor targeting antibody compositions and processes | |
BR112012008385A2 (en) | p13 kinase inhibitors and their use. | |
BR112015006060A2 (en) | kir3dl2 binding agents | |
BR112014011351A2 (en) | acc inhibitors and uses thereof | |
BRPI0911332A2 (en) | compositions and use of epas1 inhibitors | |
EA201390813A1 (en) | ANTIBODIES AND THEIR APPLICATION | |
BR112016008644A2 (en) | DYNAMINE 2 INHIBITORS FOR USE IN THE TREATMENT OF A CENTRONUCLEAR MYOPATHY; METHOD FOR IDENTIFYING OR SCREENING MOLECULES USEFUL IN THE TREATMENT OF CENTRONUCLEAR MYOPATHY, PREFERABLY XLCNM; AND PHARMACEUTICAL COMPOSITION | |
BR112012010266A2 (en) | anti-fractalquinine antibody or fkn-binding fragment thereof, pharmaceutical composition, nucleic acid, vector, host cell, methods for preparing an anti-fractalquinine antibody or fkn-binding fragment thereof, and for treating an inflammatory disorder, and, use of an antibody or fkn binding fragment thereof | |
WO2010042636A3 (en) | Telomerase inhibitors and methods of use thereof | |
EA201300436A8 (en) | JOINT CRYSTALS AND SALTS OF CCR3 INHIBITORS | |
BR112013031943A2 (en) | "g-csfr proteins and antibodies, composition comprising them and use thereof". | |
MX2013002960A (en) | Antibody compositions and methods of use. | |
BR112013000779A2 (en) | combination pharmaceutical compositions, patient treatment methods and use of activated potentiated form of angiotensin ii receptor 1 antibody and activated potentiated form of endothelial synthase antibody | |
BR112013000840A2 (en) | method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase. | |
BR112012026545A2 (en) | compositions and methods for treating copd exacerbation | |
ATE539152T1 (en) | NEW PROCEDURES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |